Jack Victory

Appalachian | @DukeSurgery Resident via @WVUMedSchool and @marshallu | @NIH MRSP Scholar | Views are my own

[Duke Surgical Oncology @DukeSurgOnc]

Dr. @michael_lidsky has been appointed Section Chief of HPB Surgery @DukeSurgOnc, effective July 10! Since 2018, he’s built one of the world’s highest-volume HAIP programs & mentored countless trainees, now on faculty nationwide. Congrats, Dr. Lidsky! 👏

#SurgOnc #DukeSurgery

[Mark Kelley @MarkKelleyMD]

This is an astounding result, but 50% of patients become resistant by one year. Improved long term survival will likely require combination with other treatments (e.g. chemotherapy, other targeted therapy, immunotherapy or metabolic therapy). It also suggests that this new class of “RAS on” inhibitors may be beneficial in many other RAS driven malignancies.

[Nicholas Hornstein @GIMedOnc]

#ASCO26

This one is special.

This is the hottest paper of 2026 and potentially in the history of pancreatic cancer.

Let’s dive in.

RASolute 302: Daraxonrasib vs investigator’s choice chemotherapy in previously treated metastatic pancreatic cancer
Abstract LBA5 (soon!)
Presentation: May 31, 2026, 3:21-3:33 PM CDT

For decades, pancreatic cancer has been where good ideas go to die.

We have optimized chemotherapy. We have sequenced chemotherapy. We have celebrated modest gains.

But the central driver of PDAC has always been sitting there in plain sight:

RAS.

More than 90% of pancreatic cancers have oncogenic RAS mutations, and until recently, we had essentially nothing direct to do about it.

Daraxonrasib is an oral RAS(ON) multiselective inhibitor targeting the active GTP-bound state of mutant and wild-type RAS.

And in RASolute 302, it delivered.

Quick hits:

📌 Phase 3 international randomized trial 500 patients with previously treated mPDAC Daraxonrasib vs investigator’s choice chemotherapy

🧬 RAS G12 population
91.8% of patients had RAS G12 mutations

📈 OS in RAS G12 population
13.2 vs 6.6 months
HR 0.40
P<0.001

📈 OS in overall population
13.2 vs 6.7 months
HR 0.40
P<0.001

📊 PFS in RAS G12 population
7.3 vs 3.5 months
HR 0.45
P<0.001

📊 PFS in overall population
7.2 vs 3.6 months
HR 0.49
P<0.001

🔥 12-month OS
Overall population: 53.2% vs 17.3%

⚠️ Toxicity matters, but this was not just more efficacy for more toxicity
Grade ≥3 AEs: 61.8% vs 69.6%
TRAEs leading to discontinuation: 1.2% vs 11.2%

This is the kind of survival curve we almost never get to see in pancreatic cancer.

This validates RAS(ON) inhibition in the most RAS-addicted major cancer. It takes a target we have talked about for decades and turns it into a clinically meaningful survival benefit in a randomized phase 3 trial.

The next questions come fast: 1L combinations, maintenance, perioperative disease, sequencing, resistance, toxicity management, and whether this becomes a new backbone.

RAS is here, and it couldn’t have come sooner.

https://t.co/Y4WJRlRRTk

@TheGutonclab @UGrewalMD @TimothyJBrownMD @OncoAlert @Onco_Nexus @ASCO
@NazliDizman @LauraAlderMD @DVAraujoMD @DrBarbiOnc @LauraEsfeller @FunchainMD @YGaritaonaindia @DrSAHaddad @jgong15 @iandresmeraz @SakditadMD @RamilaShilpakar @RohitBanwar @lungoncdoc

[Jack Victory @JackVictory21]

@SL_Provencher @MayoSurgery @DukeSurgery @DukeSurgRes Congratulations!!! They’re lucky to have you!

[Duke Surgery @DukeSurgery]

IT'S A MATCH! We’re excited to welcome 19 new interns who matched with our residency programs today across multiple specialties. We can't wait for these phenomenal surgeons in training to join us this summer!

#MatchDay2026 @DukeSurgRes @DukeVascular @DukeCTSurgery @DukeMedSchool

[Duke General Surgery Residency @DukeSurgRes]

pull up to the party #pgy1 #decadewithdave #sevenwithkevin

[Duke Surgical Oncology @DukeSurgOnc]

Good times at the Surgical Oncology Research Group social last night in downtown Durham. We may be data nerds, but we still have fun! Great representation from @DukeSurgery faculty, residents and our always outstanding @DukeMedSchool students. 🤩⭐️🤓📈📊

[Alessandro Martinino, MD PhD @AMartininoMD]

On a crisp Dutch autumn day, I finally defended my PhD thesis and completed my doctoral journey at the School of Health Professions Education, Maastricht University — four years filled with excitement, growth, connections, and lifelong friendships!

[Duke General Surgery Residency @DukeSurgRes]

PGY1 @JackVictory21 promoted to surgeon junior on this trauma laparotomy with Dr. @virginiasparker simply for wearing a headlight 💡

[Duke General Surgery Residency @DukeSurgRes]

🚨🚨Level 1 Post🚨🚨
We are THRILLED to announce that Dr. Peter Allen has been named the next Chair of @DukeSurgery!!! We look forward to continued growth, academic and clinical excellence under his leadership! @DukeSurgOnc #HometownHero #Pancreatitan

https://t.co/r7vgfWdsJp

[Duke General Surgery Residency @DukeSurgRes]

All smiles at the new intern welcome dinner with the chiefs! Hosted by our awesome program director @KN__Shah #SabistonSquad @DukeSurgery

[Jack Victory @JackVictory21]

@ashtonsamos WVU is lucky to have you! Congrats!

[Michael Lidsky, MD, FACS @michael_lidsky]

Excited to see this in print! If you’re interested in #HAI, this is a must read. A truly collaborative effort, aurthored by 75 faculty from 45 centers in 6 countries, and covers all aspects of this specialized therapy! @MichaelDAngeli2 @MSKCancerCenter @DukeCancer @DukeSurgOnc

[Duke General Surgery Residency @DukeSurgRes]

Congratulations to our graduating Chief residents!! Wonderful night of laughter and joy celebrating your accomplishments. We’ll miss you!!! 🎉🎉🎉

[National Cancer Institute @theNCI]

JUST RELEASED: This newest edition of the Annual Report to the Nation helps researchers further understand the relationship between the COVID-19 pandemic and cancer. Read the key findings from the Annual Report to the Nation on the Status of Cancer. https://t.co/jaq84UX8Bm #NCIFuture #CancerAnnualReport 🧵

[BehindTheKnife @BehindTheKnife]

Check it out ➡️ RURAL SURGERY on BTK!

Join @Cody_Mullens for Ep. 1 of 3 exploring what it means to be a rural surgeon in 2025.

🗣️ https://t.co/J1fSCIeU1W 🎧

[Jack Victory @JackVictory21]

@ajbethurum @summervshore Congrats AJ! Can’t wait to see all the success you have!

[Jack Victory @JackVictory21]

@sahitmenon @VUMCPsych @hbwardMD @Joshua_RSmith Congrats man! They are lucky to have you!!

[Jack Victory @JackVictory21]

@ByShelbyJohnson @lsusurgerydept @LSUGenSurgery Congratulations Shelby!!

[Jack Victory @JackVictory21]

I could not be more grateful and excited to be continuing my training as a resident @DukeSurgery!! Forever indebted to all along the journey. It will be hard to root for Duke basketball as a Terps fan, but I guess I can learn to manage. #Match2025 #DukeSurgery